Over a hundred years ago, high doses of salicylates were shown to lower glucose levels in diabetic patients. This should have been an important clue to link inflammation to the pathogenesis of type 2 diabetes (T2D), but the antihyperglycemic and antiinflammatory effects of salicylates were not connected to the pathogenesis of insulin resistance until recently. Together with the discovery of an important role for tissue macrophages, these new findings are helping to reshape thinking about how obesity increases the risk for developing T2D and the metabolic syndrome. The evolving concept of insulin resistance and T2D as having immunological components and an improving picture of how inflammation modulates metabolism provide new opportunities for using antiinflammatory strategies to correct the metabolic consequences of excess adiposity.
T regulatory (Treg) cells in visceral adipose tissue express high levels of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-γ, and fat-specific adaptation of Treg cells is dependent on PPAR-γ. Regulatory T (Treg) cells, a subset of T cells with immunosuppressive functions, are enriched in the adipose tissue of lean but not obese mice, where they control inflammation and metabolic disorders associated with type 2 diabetes. This paper reports that PPAR-γ (peroxisome proliferator-activated receptor-γ), the 'master regulator' of adipocyte differentiation, is a crucial molecular regulator of Treg cell accumulation, phenotype and function in fat tissue. Expression of PPAR-γ in visceral fat Treg cells contributes to the insulin-sensitizing activity of the type 2 diabetes drug pioglitazone. These results suggest that it may be possible to target a designated population of Treg cells therapeutically. Obesity and type-2 diabetes have increased markedly over the past few decades, in parallel. One of the major links between these two disorders is chronic, low-grade inflammation1. Prolonged nutrient excess promotes the accumulation and activation of leukocytes in visceral adipose tissue (VAT) and ultimately other tissues, leading to metabolic abnormalities such as insulin resistance, type-2 diabetes and fatty-liver disease. Although invasion of VAT by pro-inflammatory macrophages is considered to be a key event driving adipose-tissue inflammation and insulin resistance, little is known about the roles of other immune system cell types in these processes. A unique population of VAT-resident regulatory T (Treg) cells was recently implicated in control of the inflammatory state of adipose tissue and, thereby, insulin sensitivity2. Here we identify peroxisome proliferator-activated receptor (PPAR)-γ, the ‘master regulator’ of adipocyte differentiation, as a crucial molecular orchestrator of VAT Treg cell accumulation, phenotype and function. Unexpectedly, PPAR-γ expression by VAT Treg cells was necessary for complete restoration of insulin sensitivity in obese mice by the thiazolidinedione drug pioglitazone. These findings suggest a previously unknown cellular mechanism for this important class of thiazolidinedione drugs, and provide proof-of-principle that discrete populations of Treg cells with unique functions can be precisely targeted to therapeutic ends.
1 March 2014 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease